Description: Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle. The company markets and sells Travelan for the prevention of travellersÂ’ diarrhea. Its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. The company also has other preclinical immunotherapy pipeline products targeting immune-related diseases. Immuron Limited has a research and development collaboration agreement with the Walter Reed Army Institute of Research (WRAIR) for the development of a Shigella vaccine; and Naval Medical Research Center for the testing of Travelan in cell lines of campylobacter and enterotoxigenic escherichia coli. The company was founded in 1994 and is based in Blackburn North, Australia.
Home Page: www.immuron.com.au
IMRN Technical Analysis
62 Lygon Street
Carlton,
VIC
3053
Australia
Phone:
61 3 9824 5254
Officers
| Name | Title |
|---|---|
| Mr. Steven George Lydeamore CPA, CPA, M.B.A., MBA | Chief Exec. Officer |
| Dr. Jerry Kanellos Ph.D. | Chief Operating Officer |
| Mr. Phillip Allen Hains BBus(Acc), CA, MBA | CFO & Company Sec. |
| Mr. David Lyon | Head of Marketing |
| Dr. Dan Ruben Peres | Chief Medical Officer |
| Mr. Flavio Palumbo | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7383 |
| Price-to-Sales TTM: | 15.4352 |
| IPO Date: | 2017-06-09 |
| Fiscal Year End: | June |
| Full Time Employees: | 5 |